Trial Profile
Randomised, Multi-center study to evaluate the impact of HIV-specific T-cell vaccines and Vorinostat compared to ART alone in patients with primary HIV infection
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Oct 2019
Price :
$35
*
At a glance
- Drugs HIV vaccine (Primary) ; MVA HIV vaccine (Primary) ; Vorinostat (Primary) ; Antiretrovirals
- Indications HIV infections
- Focus Therapeutic Use
- Acronyms RIVER
- 07 Mar 2019 Results of a RIVER GUT substudy (n=11) presented at the 26th Conference on Retroviruses and Opportunistic Infections
- 28 Aug 2018 New trial record
- 27 Jul 2018 Primary endpoint ((log10 total HIV-DNA copies/million from CD4+ T-cells at weeks PR-16&18)) has not been met, according to the results presented at the 22nd International AIDS Conference